Crispr Therapeutics upgraded to Outperform from In Line at Evercore ISI
Evercore ISI analyst Liisa Bayko upgraded Crispr Therapeutics (CRSP) to Outperform from In Line with a price target of $99, up from $60.
Business Insider16d
Ironwood Pharma (IRWD) Gets a Buy from Craig-Hallum
In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Ironwood Pharma (IRWD – Research Report), with a price target of $7.00. The company’s shares closed ...
Business Insider25d
AI can call the shots on drug making because it 'doesn't have a career at stake,' major pharma CEO says
Paul Hudson, CEO of the pharmaceutical firm Sanofi, has an argument for letting AI make top-level decisions in medicine: It has no attachments. Speaking at a panel in Davos on Tuesday, Hudson said ...
Microsoft26d
8 Components of great AI art prompts
The first component of a successful AI art prompt is clarity in the query. A clear prompt ensures that Copilot understands exactly what you want to create. Rather than using vague or ambiguous ...